The estimated Net Worth of Anjeza Gjino is at least $102 mil dollars as of 25 February 2021. Ms Gjino owns over 1,824 units of Cyclerion Therapeutics stock worth over $94,955 and over the last 4 years she sold CYCN stock worth over $7,296.
Ms has made over 1 trades of the Cyclerion Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently she sold 1,824 units of CYCN stock worth $7,296 on 25 February 2021.
The largest trade she's ever made was selling 1,824 units of Cyclerion Therapeutics stock on 25 February 2021 worth over $7,296. On average, Ms trades about 608 units every 0 days since 2021. As of 25 February 2021 she still owns at least 31,599 units of Cyclerion Therapeutics stock.
You can see the complete history of Ms Gjino stock trades at the bottom of the page.
Anjeza Gjino is the CFO & Corp. Sec. (Maternity Leave of Absence) at Cyclerion Therapeutics.
Ms Gjino is 38, she's been the CFO & Corp. Sec. (Maternity Leave of Absence) of Cyclerion Therapeutics since . There are 15 older and no younger executives at Cyclerion Therapeutics. The oldest executive at Cyclerion Therapeutics, Inc. is George Conrades, 81, who is the Independent Director.
Anjeza's mailing address filed with the SEC is C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA, 02142.
Over the last 6 years, insiders at Cyclerion Therapeutics have traded over $240,273 worth of Cyclerion Therapeutics stock and bought 4,653,203 units worth $33,009,775 . The most active insiders traders include Peter M Hecht, Mark G Currie y Terrance Mcguire. On average, Cyclerion Therapeutics executives and independent directors trade stock every 84 days with the average trade being worth of $749,841. The most recent stock trade was executed by Terrance Mcguire on 9 August 2023, trading 8 units of CYCN stock currently worth $27.
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Cyclerion Therapeutics executives and other stock owners filed with the SEC include: